Revolution Medicines
RVMD | NASDAQ
$166.87
-$5.42 (-3.15%)
At close: Nov 16, 2026, 4:00 PM ET
$167.80
+$0.93 (+0.56%)
After-hours:
Nov 16, 2026, 7:57 PM ET
Revolution Medicines Company Profile
Company profile explainedCompany Profile
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Key Executives
| Name | Position |
|---|---|
| Mark A. Goldsmith | Chief Executive Officer, President & Chairman |
| Jack Anders | Chief Financial Officer |
| Margaret A. Horn | Chief Operating Officer |
| Walter Reiher | Chief Information Officer |
| Jan Smith | Chief Scientific Officer |
| Jeff Cislini | Senior Vice President, General Counsel & Corporate Secretary |
| Kevan Shokat | Academic Co-Founder & Member of Scientific Advisory Board |
| Martin D. Burke | Co-Founder & Chairman of Scientific Advisory Board |
| Michael A. Fischbach | Academic Co-Founder & Member of Scientific Advisory Board |
| Stephen Kelsey Path. FRCP | Senior Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 28, 2026 | 4 | Filing |
| Oct 13, 2026 | 8-K | Current Report |
| Oct 01, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 28, 2026 | 4 | Filing |
| Sep 24, 2026 | 4 | Filing |
| Sep 22, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
Revolution Medicines
| Country | United States |
| IPO Date | Feb 13, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 883 |
| CEO | Mark A. Goldsmith |
Contact Details
700 Saginaw Drive Redwood City,
California 94063 United States
Stock Details
| Ticker Symbol | RVMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001628171 |
| CUSIP Number | 76155X100 |
| ISIN Number | US76155X1000 |
| SIC Code | 2836 |
Recent News
- 12 hours ago / globenewswire.comEuropean Commission Approves Revolution Medicines' RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
- 16 hours ago / seekingalpha.comRevolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
- 4 days ago / seekingalpha.comRevolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are High
- 6 days ago / seekingalpha.comRevolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
- 6 days ago / zacks.comWall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet
- 9 days ago / fool.comRevolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?
- 11 days ago / seekingalpha.comRevolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It
- 11 days ago / zacks.comRVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake
- 12 days ago / marketbeat.comWhat Revolution Medicines (RVMD) Said on Its Q3 Earnings Call
- 12 days ago / seekingalpha.comRevolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript
Add to Watchlist
Select watchlists to add or remove RVMD